Applicants,Chemical_Name,Funding_requested_for,Pharmaceutical,Priority_List,Schedules,Therapeutic_group
ABBVIE LIMITED,Venetoclax (with widened access to azacitidine),"Acute myeloid leukaemia, newly diagnosed, ineligible for intensive induction chemotherapy",Venetoclax (with widened access to azacitidine) (Venclexta),,Community and Hospital,Oncology Agents and Immunosuppressants
